English
Regional settings| Spread | 0.12 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ £5,000.00 Short position overnight fee ~ £4,000.00 | -0.025295% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ £5,000.00 Short position overnight fee ~ £4,000.00 | 0.003377% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | GBP | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 12.66 |
| Open | 12.58 |
| 1-Year Change | -24.85% |
| Day's Range | 12.58 - 12.82 |
Victrex plc is a United Kingdom-based polymer solutions company. The Company is focused on markets of automotive, aerospace, energy, (including manufacturing and engineering), electronics and medical. It operates through two segments: Industrial and Medical. The Industrial segment focuses on its energy and industrial, value added resellers (var), automotive, aerospace and electronics markets. The Medical segment focuses on providing specialist solutions for medical device manufacturers. The Company develops solutions in polyetheretherketone (PEEK) and polyaryletherketone (PAEK) based polymers, and selected semi-finished and finished parts. The Company serves in more than 40 countries across the world having geographical locations in the United Kingdom; Europe, Middle East and Africa (EMEA); Americas, and Asia-Pacific.
BRIEF: For the fiscal year ended 30 September 2021, Victrex plc revenues increased 18% to £311.2M. Net income increased 35% to £73.2M. Revenues reflect Industrial segment increase of 18% to £255.2M, Medical segment increase of 3% to £51.1M, Europe, Middle East and Africa(EMEA) segment increase of 23% to £139.3M, Asia-Pacific segment increase of 15% to £85.9M. Net income benefited from Restructuring costs decrease from £9.8M (expense) to £800K (income).
